Table 1.
Baseline Characteristics of Trial Population
| Characteristic | Liraglutide (n = 24) | Sitagliptin (n = 27) | Insulin glargine (n = 24) |
|---|---|---|---|
| n (male/female) | 17/7 | 21/6 | 14/10 |
| Age (years) | 43.1 ± 9.7 | 45.7 ± 9.2 | 45.6 ± 7.6 |
| Duration of T2DM (years) | 3.3 ± 3.5 | 4.3 ± 3.8 | 5.8 ± 4.5 |
| Weight (kg) | 86.6 ± 12.9 | 88.2 ± 13.6 | 85.6 ± 14.2 |
| BMI (kg/m2) | 30.1 ± 3.3 | 29.7 ± 2.8 | 29.6 ± 3.5 |
| Waist (cm) | 101.7 ± 7.9 | 102.8 ± 8.3 | 102.9 ± 9.9 |
| SBP (mm Hg) | 125.2 ± 7.6 | 124.9 ± 10.7 | 126.9 ± 7.9 |
| DBP (mm Hg) | 78.1 ± 7.3 | 82.3 ± 7.6 | 83.5 ± 8.3 |
| AST (mmol/L) | 31.1 ± 11.7 | 34.4 ± 16.9 | 33.2 ± 17.4 |
| ALT (mmol/L) | 43.2 ± 21·2 | 46.0 ± 25.5 | 39.5 ± 25.7 |
| FPG (mmol/L) | 8.6 ± 2.8 | 8.4 ± 2.5 | 8.9 ± 2.2 |
| PPG (mmol/L) | 13.2 ± 3.1 | 13.7 ± 3.7 | 14.6 ± 3.9 |
| HbA1c | 7.8% ± 1.4% | 7.6% ± 0.9% | 7.7% ± 0.9% |
| TC (mmol/L) | 4.4 ± 0.9 | 4.9 ± 1.2 | 4.7 ± 1.2 |
| TG (mmol/L) | 2.3 ± 1.1 | 2.6 ± 1.4 | 2.9 ± 2.3 |
| LDL‐C (mmol/L) | 2.7 ± 0.8 | 3.1 ± 0.7 | 2.6 ± 1.0 |
| HDL‐C (mmol/L) | 1.1 ± 0.2 | 1.2 ± 0.6 | 1.1 ± 0.4 |
| MRI‐PDFF | 15.4% ± 5.6% | 15.5% ± 5.6% | 14.9% ± 5.5% |
| SAT (cm2) | 239.9 ± 69.0 | 239.5 ± 69.3 | 212.7 ± 57.7 |
| VAT (cm2) | 171.4 ± 27.8 | 153.4 ± 31.5 | 188.4 ± 74.7 |
| FIB‐4 | 0.7 9± 0.31 | 0.98 ± 0.42 | 1.10 ± 0.62 |
| NFS | −0.78 ± 0.81 | −1.55 ± 0.78 | −0.95 ± 0.85 |
Values are presented as mean ± SD.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; DBP, diastolic blood pressure; FIB‐4, FIB4 Index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; MRI‐PDFF, magnetic resonance imaging–estimated proton density fat fraction; NFS, NAFLD Fibrosis Score; PPG, postprandial plasma glucose; SAT, subcutaneous adipose tissue; SBP, systolic blood pressure; SD, standard deviation; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglyceride; VAT, visceral adipose tissue.